Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350415 · ClinicalTrials.gov registry record · Phase 3
A Double Blind Study for the Treatment of Acute Ulcerative Colitis
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 772
- Enrollment target
NCT00350415 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 772 participants.
The verdict
NCT00350415, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 772 participants
- Enrollment target
Study Summary
A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).
Interventions
- DRUG Mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 772 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350415
The ClinicalTrials.gov registry entry for NCT00350415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 772 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mesalamine is the first listed.
NCT00350415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350415 about?
NCT00350415 is a clinical study titled "A Double Blind Study for the Treatment of Acute Ulcerative Colitis". A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).
What is the current status of trial NCT00350415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 772 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00350415?
The interventions under investigation include: Mesalamine (DRUG).
Who is sponsoring clinical trial NCT00350415?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.